1G1H image
Deposition Date 2000-10-11
Release Date 2001-01-17
Last Version Date 2024-11-13
Entry Detail
PDB ID:
1G1H
Title:
CRYSTAL STRUCTURE OF PROTEIN TYROSINE PHOSPHATASE 1B COMPLEXED WITH A BIS-PHOSPHORYLATED PEPTIDE (ETD(PTR)(PTR)RKGGKGLL) FROM THE INSULIN RECEPTOR KINASE
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
(Taxon ID: )
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.40 Å
R-Value Free:
0.24
R-Value Work:
0.20
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:PROTEIN TYROSINE PHOSPHATASE 1B
Gene (Uniprot):PTPN1
Mutations:C215A
Chain IDs:A
Chain Length:298
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:BI-PHOSPHORYLATED PEPTIDE FROM THE INSULIN RECEPTOR KINASE
Chain IDs:B
Chain Length:13
Number of Molecules:1
Biological Source:
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR B TYR O-PHOSPHOTYROSINE
Primary Citation
Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B.
Mol.Cell 6 1401 1412 (2000)
PMID: 11163213 DOI: 10.1016/S1097-2765(00)00137-4

Abstact

The protein tyrosine phosphatase PTP1B is responsible for negatively regulating insulin signaling by dephosphorylating the phosphotyrosine residues of the insulin receptor kinase (IRK) activation segment. Here, by integrating crystallographic, kinetic, and PTP1B peptide binding studies, we define the molecular specificity of this reaction. Extensive interactions are formed between PTP1B and the IRK sequence encompassing the tandem pTyr residues at 1162 and 1163 such that pTyr-1162 is selected at the catalytic site and pTyr-1163 is located within an adjacent pTyr recognition site. This selectivity is attributed to the 70-fold greater affinity for tandem pTyr-containing peptides relative to mono-pTyr peptides and predicts a hierarchical dephosphorylation process. Many elements of the PTP1B-IRK interaction are unique to PTP1B, indicating that it may be feasible to generate specific, small molecule inhibitors of this interaction to treat diabetes and obesity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures